Literature DB >> 19700011

Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.

Jo-David Fine1, Jemima E Mellerio.   

Abstract

It is well known, primarily via case reports and limited case series, that nonepithelial tissues may become injured in patients with epidermolysis bullosa. Only recently, however, have there been data generated from large, well characterized cohorts. Our objective is to provide dermatologists with a comprehensive review of each of these major extracutaneous complications, with a summary of the pertinent literature and evidence-based recommendations for surveillance, evaluation, and management. Some epidermolysis bullosa subtypes are at risk for severe injury of the bone marrow, musculoskeletal system, heart, kidney, and teeth, and for the development of squamous cell carcinoma, basal cell carcinoma, or malignant melanoma. If untreated, significant morbidity or mortality may result.

Entities:  

Mesh:

Year:  2009        PMID: 19700011     DOI: 10.1016/j.jaad.2009.03.053

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  49 in total

1.  BPAG1-e restricts keratinocyte migration through control of adhesion stability.

Authors:  Magdalene Michael; Rumena Begum; Kenneth Fong; Celine Pourreyrone; Andrew P South; John A McGrath; Maddy Parsons
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

Review 2.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

3.  Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Gabriela Petrof; Su M Lwin; Magdalena Martinez-Queipo; Alya Abdul-Wahab; Simon Tso; Jemima E Mellerio; Ineke Slaper-Cortenbach; Jaap J Boelens; Jakub Tolar; Paul Veys; Mercy Ofuya; Janet L Peacock; Anna E Martinez; John A McGrath
Journal:  J Invest Dermatol       Date:  2015-04-23       Impact factor: 8.551

4.  A consensus approach to wound care in epidermolysis bullosa.

Authors:  Elena Pope; Irene Lara-Corrales; Jemima Mellerio; Anna Martinez; Gregory Schultz; Robert Burrell; Laurie Goodman; Patricia Coutts; John Wagner; Upton Allen; Gary Sibbald
Journal:  J Am Acad Dermatol       Date:  2012-03-02       Impact factor: 11.527

Review 5.  [Hereditary epidermolysis bullosa in school children and adolescents. Clinical picture and interdisciplinary management].

Authors:  H Ott; C Eich; K Schriek; B Ludwikowski
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

6.  Rare case of dysphagia, skin blistering, missing nails in a young boy.

Authors:  Jasbir Makker; Bharat Bajantri; Prospere Remy
Journal:  World J Gastrointest Endosc       Date:  2015-02-16

7.  Toward treatment and cure of epidermolysis bullosa.

Authors:  Jouni Uitto
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-11       Impact factor: 11.205

8.  TALEN-based gene correction for epidermolysis bullosa.

Authors:  Mark J Osborn; Colby G Starker; Amber N McElroy; Beau R Webber; Megan J Riddle; Lily Xia; Anthony P DeFeo; Richard Gabriel; Manfred Schmidt; Christof von Kalle; Daniel F Carlson; Morgan L Maeder; J Keith Joung; John E Wagner; Daniel F Voytas; Bruce R Blazar; Jakub Tolar
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

9.  Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa.

Authors:  G Rodari; S Guez; F Manzoni; K K Chalouhi; E Profka; S Bergamaschi; S Salera; G Tadini; F M Ulivieri; A Spada; C Giavoli; S Esposito
Journal:  Osteoporos Int       Date:  2016-12-23       Impact factor: 4.507

Review 10.  Inherited epidermolysis bullosa.

Authors:  Jo-David Fine
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.